Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

NCT01527539 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: biphasic insulin aspart 30

Sponsor

Novo Nordisk A/S